CT biomarkers for classifying and predicting bronchiectasis outcomes
The Clinical Significance of CT-based Biomarkers in the Classification and Prognosis of Bronchiectasis
This project will test whether features seen on chest CT scans can help classify bronchiectasis and predict how adults with bronchiectasis will do over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06346938 on ClinicalTrials.gov |
What this trial studies
This observational study will collect high-resolution chest CT scans and clinical data from adults with CT-confirmed bronchiectasis at Wuhan Union Hospital. Investigators will analyze imaging features such as emphysema, mucus plugs, dendritic signs, and adjacent parenchymal changes and relate them to clinical severity, infection risk, and disease progression during follow-up. Patients with major comorbid respiratory diseases, prior pulmonary surgery, traction bronchiectasis from fibrosis, or serious organ dysfunction are excluded to focus on non-traction bronchiectasis. The aim is to derive CT-based biomarkers that improve classification and prognostic stratification to support more personalized care.
Who should consider this trial
Good fit: Adults (18+) with bronchiectasis confirmed by high-resolution CT who can undergo CT scanning and provide informed consent, and who do not have the listed exclusion conditions, are ideal candidates.
Not a fit: Patients with prior lung surgery, lung cancer, asthma, traction bronchiectasis from pulmonary fibrosis, major organ dysfunction, or missing essential clinical data are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, CT biomarkers could help doctors personalize prognosis and treatment plans for people with bronchiectasis.
How similar studies have performed: Previous imaging studies have linked CT features like emphysema and mucus plugging to worse outcomes in bronchiectasis, but a standardized CT-biomarker system for prognosis is not yet widely established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years and above; * Can cooperate with CT scan; * Bronchiectasis confirmed by high-resolution computed tomography of the lungs; * Can provide written informed consent Exclusion Criteria: * Pulmonary surgery; * Patients with lung cancer, asthma and other respiratory diseases; * Tractive bronchiectasis caused by pulmonary fibrosis; * Patients with malignant tumors or serious dysfunction of the heart, brain, kidney and other important systems can not cooperate with the completion of this study； * Lack of important clinical information.
Where this trial is running
Wuhan, Hubei
- Wuhan Union Hospital — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: xiaorong Wang — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Study coordinator: xiaorong Wang
- Email: rong-100@163.com
- Phone: 18627195231
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.